Law360, New York (November 10, 2010, 12:42 PM ET) -- A federal appeals court has ruled that the U.S. Food and Drug Administration was correct to grant five years of market exclusivity to Shire PLC's attention deficit hyperactivity disorder drug Vyvanse.
In an order issued Tuesday, a three-judge panel of the U.S. Court of Appeals for the District of Columbia Circuit declined to overturn a lower court's decision granting summary judgment to the FDA and Shire, saying there was no merit to a generic-drug maker's claims that Vyvanse was not a new drug and didn't deserve...
DC Circ. Upholds Exclusivity For ADHD Drug Vyvanse
To view the full article, take a free trial now.
